Literature DB >> 16996554

Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques.

Flavia Ferrantelli1, Kathleen A Buckley, Robert A Rasmussen, Alistair Chalmers, Tao Wang, Pei-Lin Li, Alison L Williams, Regina Hofmann-Lehmann, David C Montefiori, Lisa A Cavacini, Hermann Katinger, Gabriela Stiegler, Daniel C Anderson, Harold M McClure, Ruth M Ruprecht.   

Abstract

In a primate model of postnatal virus transmission, we have previously shown that 1 h post-exposure prophylaxis (PEP) with a triple combination of neutralizing monoclonal antibodies (nmAbs) conferred sterilizing protection to neonatal macaques against oral challenge with pathogenic simian-human immunodeficiency virus (SHIV). Here, we show that nmAbs can also partially protect SHIV-exposed newborn macaques against infection or disease, when given as 12 or 24 h PEP, respectively. This work delineates the potential and the limits of passive immunoprophylaxis with nmAbs. Even though 24 h PEP with nmAbs did not provide sterilizing immunity to neonatal monkeys, it contained viremia and protected infants from acute disease. Taken together with our results from other PEP studies, these data show that the success of passive immunization depends on the nmAb potency/dose and the time window between virus exposure and start of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996554     DOI: 10.1016/j.virol.2006.07.056

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

2.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

Review 3.  Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Authors:  George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

4.  Challenges of antibody-mediated protection against HIV-1.

Authors:  George K Lewis
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

5.  HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies.

Authors:  Genevieve G Fouda; Nicole L Yates; Justin Pollara; Xiaoying Shen; Glenn R Overman; Tatenda Mahlokozera; Andrew B Wilks; Helen H Kang; Jesus F Salazar-Gonzalez; Maria G Salazar; Linda Kalilani; Steve R Meshnick; Beatrice H Hahn; George M Shaw; Rachel V Lovingood; Thomas N Denny; Barton Haynes; Norman L Letvin; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Sallie R Permar
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

Review 6.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

7.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

8.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Authors:  C Moog; N Dereuddre-Bosquet; J-L Teillaud; M E Biedma; V Holl; G Van Ham; L Heyndrickx; A Van Dorsselaer; D Katinger; B Vcelar; S Zolla-Pazner; I Mangeot; C Kelly; R J Shattock; R Le Grand
Journal:  Mucosal Immunol       Date:  2013-04-17       Impact factor: 7.313

9.  Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.

Authors:  Laurent Gros; Mireia Pelegrin; Henri-Alexandre Michaud; Stéphanie Bianco; Javier Hernandez; Chantal Jacquet; Marc Piechaczyk
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

10.  Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.

Authors:  Paul W Denton; John F Krisko; Daniel A Powell; Melissa Mathias; Youn Tae Kwak; Francisco Martinez-Torres; Wei Zou; Deborah A Payne; Jacob D Estes; J Victor Garcia
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.